JP2010526101A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526101A5 JP2010526101A5 JP2010506688A JP2010506688A JP2010526101A5 JP 2010526101 A5 JP2010526101 A5 JP 2010526101A5 JP 2010506688 A JP2010506688 A JP 2010506688A JP 2010506688 A JP2010506688 A JP 2010506688A JP 2010526101 A5 JP2010526101 A5 JP 2010526101A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- compound
- composition
- unit dose
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91564907P | 2007-05-02 | 2007-05-02 | |
| US94792107P | 2007-07-03 | 2007-07-03 | |
| PCT/US2008/062518 WO2008137753A2 (en) | 2007-05-02 | 2008-05-02 | Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010526101A JP2010526101A (ja) | 2010-07-29 |
| JP2010526101A5 true JP2010526101A5 (https=) | 2011-06-23 |
Family
ID=39587015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506688A Withdrawn JP2010526101A (ja) | 2007-05-02 | 2008-05-02 | 直接作用型および可逆的ｐ２ｙ１２阻害剤の静脈および経口投与 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20090048216A1 (https=) |
| EP (1) | EP2079464A2 (https=) |
| JP (1) | JP2010526101A (https=) |
| KR (1) | KR20100029746A (https=) |
| CN (1) | CN101795682A (https=) |
| AU (1) | AU2008247483A1 (https=) |
| BR (1) | BRPI0811476A2 (https=) |
| CA (1) | CA2686203A1 (https=) |
| CO (1) | CO6241104A2 (https=) |
| EA (1) | EA200901473A1 (https=) |
| EC (1) | ECSP099778A (https=) |
| GT (1) | GT200900284A (https=) |
| IL (1) | IL201834A0 (https=) |
| MA (1) | MA31663B1 (https=) |
| MX (1) | MX2009011843A (https=) |
| TN (1) | TN2009000451A1 (https=) |
| WO (1) | WO2008137753A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1951254E (pt) * | 2005-11-03 | 2012-04-12 | Portola Pharm Inc | [4-(6-halo-7-substituído-2,4-dioxo-1,4-di-hidro-2hquinazolin- 3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilureias e formas e métodos relacionados com as mesmas |
| CA2678492A1 (en) * | 2007-03-06 | 2008-09-12 | Novartis Ag | Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions |
| US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
| WO2008137809A2 (en) * | 2007-05-02 | 2008-11-13 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof |
| US9427448B2 (en) * | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| MX2011006995A (es) * | 2008-12-30 | 2011-09-27 | Thrombologic Aps | Metodos para identificar pacientes criticamente enfermos en riesgo incrementado de desarrollar nsuficiencia organica y compuestos para el tratamiento de la misma. |
| BR112012011298B1 (pt) | 2009-11-11 | 2021-12-14 | Chiesi Farmaceutici S.P.A. | Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos |
| US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| EP2633857B1 (en) * | 2009-12-23 | 2015-08-12 | ratiopharm GmbH | Solid pharmaceutical dosage form of ticagrelor and acetylsalicylic acid |
| US20130165459A1 (en) | 2010-01-12 | 2013-06-27 | Norvartis Pharma Ag | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
| WO2011137459A1 (en) * | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
| EP2646827A1 (en) | 2010-12-01 | 2013-10-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and kits for determining platelet susceptibility to activation in a patient |
| JP2013544271A (ja) * | 2010-12-03 | 2013-12-12 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 式（ｉ）の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法 |
| MA49887A (fr) | 2017-03-15 | 2020-06-24 | Idorsia Pharmaceuticals Ltd | Administration sous-cutanée d'un antagoniste du récepteur p2y12 |
| MA49452A (fr) | 2017-06-23 | 2021-05-05 | Chiesi Farm Spa | Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire |
| CN107462648B (zh) * | 2017-08-21 | 2019-09-27 | 盐城锦明药业有限公司 | 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| PT1951254E (pt) | 2005-11-03 | 2012-04-12 | Portola Pharm Inc | [4-(6-halo-7-substituído-2,4-dioxo-1,4-di-hidro-2hquinazolin- 3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilureias e formas e métodos relacionados com as mesmas |
-
2008
- 2008-05-02 CA CA002686203A patent/CA2686203A1/en not_active Abandoned
- 2008-05-02 JP JP2010506688A patent/JP2010526101A/ja not_active Withdrawn
- 2008-05-02 EP EP08747561A patent/EP2079464A2/en not_active Withdrawn
- 2008-05-02 CN CN200880023071A patent/CN101795682A/zh active Pending
- 2008-05-02 US US12/114,630 patent/US20090048216A1/en not_active Abandoned
- 2008-05-02 BR BRPI0811476-5A2A patent/BRPI0811476A2/pt not_active IP Right Cessation
- 2008-05-02 KR KR1020097025059A patent/KR20100029746A/ko not_active Withdrawn
- 2008-05-02 EA EA200901473A patent/EA200901473A1/ru unknown
- 2008-05-02 WO PCT/US2008/062518 patent/WO2008137753A2/en not_active Ceased
- 2008-05-02 AU AU2008247483A patent/AU2008247483A1/en not_active Abandoned
- 2008-05-02 MX MX2009011843A patent/MX2009011843A/es not_active Application Discontinuation
-
2009
- 2009-10-29 IL IL201834A patent/IL201834A0/en unknown
- 2009-10-30 TN TNP2009000451A patent/TN2009000451A1/fr unknown
- 2009-10-30 GT GT200900284A patent/GT200900284A/es unknown
- 2009-11-26 MA MA32377A patent/MA31663B1/fr unknown
- 2009-12-02 CO CO09137697A patent/CO6241104A2/es not_active Application Discontinuation
- 2009-12-02 EC EC2009009778A patent/ECSP099778A/es unknown
-
2011
- 2011-09-16 US US13/235,305 patent/US20120009172A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010526101A5 (https=) | ||
| US12220392B2 (en) | Combination composition | |
| JP2020033360A5 (https=) | ||
| JP2008535867A5 (https=) | ||
| JP2011173928A5 (https=) | ||
| JP2009102342A5 (https=) | ||
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| JP2014515373A5 (https=) | ||
| JP2020510043A5 (https=) | ||
| JP2022535894A5 (https=) | ||
| ES2671926T3 (es) | Comprimido recubierto en seco que contiene tegafur, gimeracilo y oteracilo potásico | |
| ES2508490T3 (es) | Formulación de trimetazidina con diferentes perfiles de liberación | |
| AU2011274652B2 (en) | A combination composition comprising ibuprofen and paracetamol | |
| AU2010277725B2 (en) | Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients | |
| CN102247330B (zh) | 一种以红花黄色素为原料制备的缓释片剂及其制备方法 | |
| TWI631944B (zh) | 氯硝柳胺及其衍生物的用途 | |
| KR20120089444A (ko) | 정맥내 이부프로펜에 의한 위독한 환자의 치료방법 | |
| ES2782898T3 (es) | Métodos de administración de compuestos agonistas de la trombopoyetina | |
| ES2952013T3 (es) | Combinación de ibuprofeno y tramadol para aliviar el dolor | |
| Myers et al. | Infection and pheochromocytoma | |
| JP2022540854A5 (https=) | ||
| JP2008527034A5 (https=) | ||
| CN103933034B (zh) | 一种含有木犀草素的药物组合物及应用 | |
| Sparagana | Superior vena cava syndrome caused by mediastinal goiter | |
| BRPI0617184A2 (pt) | formulação de pralnacasan com liberação retardada |